Fundraising Fox
Primmune Therapeutics
Carlsbad, US · Founded 2017 · 9 employees on LinkedIn · 6 known investors
Find your way into Primmune Therapeutics
6 people in our graph share verified history with the Primmune Therapeutics team — schools, employers, funds. One of them is your warm intro.
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Founders & leadership
Primmune Therapeutics was founded in 2017 by James Appleman, Paulo Rangel, and Stephen Webber.
Board
Investors · 6
How we know: BioRock Ventures's portfolio page · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Funding
SEC filings, press & company announcements$20.1M disclosed across 5 of 7 rounds · 2017–2026
- Undisclosed amountSeries BJan 2026 · 2 sourcesSource ↗
▶$13MraisedNov 2020 · 12 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer
- Scott MorensteinDirector
- Andrew RubinsteinDirector
- Amir NashatDirector
- Offering amount
- $24M
- Amount sold
- $13M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.1MraisedMar 2020 · 19 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $4M
- Amount sold
- $1.1M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2MraisedMar 2020 · 17 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $4M
- Amount sold
- $2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.5MraisedMar 2020 · 2 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $3.5M
- Amount sold
- $2.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.5MraisedJan 2018 · 36 investors · Other TechnologyRule 506(b)
- Todd J HarrisDirector
- Paulo S RangelExecutive Officer, Director
- James R ApplemanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Proceeds to insiders
- $360K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Primmune Therapeutics do?
- Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
- Who founded Primmune Therapeutics?
- Primmune Therapeutics was founded by James Appleman, Paulo Rangel, Stephen Webber in 2017.
- Who are Primmune Therapeutics's investors?
- Primmune Therapeutics's investors include BioBrit, BioRock Ventures, Samsara BioCapital, Bioqube Ventures, Oberland Capital, Polaris Partners.
- How much funding has Primmune Therapeutics raised?
- Primmune Therapeutics has disclosed $20.1M raised across 5 of its 7 known rounds.
- Where is Primmune Therapeutics headquartered?
- Primmune Therapeutics is headquartered in Carlsbad, US.